» Authors » Megan E Barefoot

Megan E Barefoot

Explore the profile of Megan E Barefoot including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 46
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain S, Barefoot M, Varghese R, Ressom H
Proceedings (IEEE Int Conf Bioinformatics Biomed) . 2023 Sep; 2022:444-449. PMID: 37663782
Hepatocellular carcinoma (HCC) has been an approved indication for the administration of immunotherapy since 2017, but biomarkers that predict therapeutic response have remained limited. Understanding and characterizing the tumor immune...
2.
Yuan M, Barefoot M, Peterson K, Campbell M, Blancato J, Chen M, et al.
Int J Mol Sci . 2023 Jul; 24(14). PMID: 37511268
Mutations in the gene ankyrin repeat domain containing 11 (/) play a role in neurodegenerative disorders, and its loss of heterozygosity and low expression are seen in some cancers. Here,...
3.
Denis M, Varghese R, Barefoot M, Tadesse M, Ressom H
Annu Int Conf IEEE Eng Med Biol Soc . 2022 Sep; 2022:81-86. PMID: 36085997
Recent studies have confirmed the role of miRNA regulation of gene expression in oncogenesis for various cancers. In parallel, prior knowledge about relationships between miRNA and mRNA have been accumulated...
4.
Martinez Roth S, Vietsch E, Barefoot M, Schmidt M, Park M, Ramesh A, et al.
Gastrointest Disord (Basel) . 2022 May; 3(3):100-112. PMID: 35531260
Thoracic high dose radiation therapy (RT) for cancer has been associated with early and late cardiac toxicity. To assess altered rates of cardiomyocyte cell death due to RT we monitored...
5.
Lin Y, Schmidt M, Sharif G, Vietsch E, Kiliti A, Barefoot M, et al.
Oncoimmunology . 2022 Feb; 11(1):2027136. PMID: 35127250
Pancreatic cancer remains largely unresponsive to immune modulatory therapy attributable in part to an immunosuppressive, desmoplastic tumor microenvironment. Here, we analyze mechanisms of cancer cell-autonomous resistance to T cells. We...
6.
Varghese R, Barefoot M, Jain S, Chen Y, Zhang Y, Alley A, et al.
Front Genet . 2021 Sep; 12:708326. PMID: 34557219
Pathologic alterations in epigenetic regulation have long been considered a hallmark of many cancers, including hepatocellular carcinoma (HCC). In a healthy individual, the relationship between DNA methylation and microRNA (miRNA)...
7.
Barefoot M, Loyfer N, Kiliti A, McDeed 4th A, Kaplan T, Wellstein A
Front Genet . 2021 Aug; 12:671057. PMID: 34386036
Detection of cellular changes in tissue biopsies has been the basis for cancer diagnostics. However, tissue biopsies are invasive and limited by inaccuracies due to sampling locations, restricted sampling frequency,...
8.
Varghese R, Zhou Y, Chen Y, Barefoot M, Tadesse M, Ressom H
Annu Int Conf IEEE Eng Med Biol Soc . 2020 Oct; 2020:5320-5325. PMID: 33019185
In addition to socioeconomic influences, biological factors are believed to play a role in health disparities. In this paper, we investigate miRNA, mRNA, and DNA methylation patterns that contribute to...
9.
Chen Y, Barefoot M, Varghese R, Wang K, Di Poto C, Ressom H
Annu Int Conf IEEE Eng Med Biol Soc . 2020 Oct; 2020:5300-5303. PMID: 33019180
Compared to European-Americans (EAs), the incidence of hepatocellular carcinoma (HCC) is higher in African-Americans (AAs) and is associated with more advanced tumor stage at diagnosis and lower survival rates. The...
10.
Barefoot M, Varghese R, Zhou Y, Di Poto C, Ferrarini A, Ressom H
Annu Int Conf IEEE Eng Med Biol Soc . 2020 Jan; 2019:1350-1354. PMID: 31946143
The threat of Hepatocellular Carcinoma (HCC) is a growing problem, with incidence rates anticipated to near double over the next two decades. The increasing burden makes discovery of novel diagnostic,...